BPTH
$3.99
Bio-Path
($.12)
(2.92%)
BPTH
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.83)
Revenue:  $0.00 Mil
Friday
Nov 13
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when BPTH reports earnings?
Beat
Meet
Miss

Where is BPTH's stock price going from here?
Up
Flat
Down
Stock chart of BPTH
Analysts
Summary of analysts' recommendations for BPTH
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized.
Peers
InterCeptRegeneron PharmaceuticalsBioMarin PharmaceuticalVertex PharmaceuticalsJohnson & JohnsonZoetisUltragenyx PharmaceuticalBristol-Myers SquibbCatalentMerck & Co.